LRP1B
LRP1B (Low-density lipoprotein receptor-related protein 1B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.
Overview
Potential cell surface proteins that bind and internalise ligands in the process of receptor-mediated endocytosis.
CIViC holds 4 clinical evidence items and 0 assertions across 4 variants, naming Immune Checkpoint Inhibitor and Doxorubicin. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.97, affected pathway 0.76, genetic association 0.44, somatic mutation 0.88). IntOGen calls it a driver in 70 cohorts (39 activating, 27 loss-of-function), covering Acute Myeloid Leukaemia, Basal Cell Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cholangiocarcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · LRP1B (Low-density lipoprotein receptor-related protein 1B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.
- 1 · What it is
LRP1B (Low-density lipoprotein receptor-related protein 1B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.
- 2 · What goes wrong in cancer
Potential cell surface proteins that bind and internalise ligands in the process of receptor-mediated endocytosis. Location: Membrane (UniProt).
- 3 · How drugs use it
No product in this corpus aims at LRP1B yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:6693 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NZR2 (protein name, function text, keywords and locations (REST API)); CIViC gene LRP1B (4 evidence items, 0 assertions, 4 variants; diseases: Glioblastoma, Ovarian Cancer, Lung Adenocarcinoma, Solid Tumour (GraphQL API, CC0)); Open Targets ENSG00000168702 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.62, gastric cancer 0.55, oesophageal cancer 0.53, prostate cancer 0.56, ovarian cancer 0.55, melanoma 0.66 (GraphQL API, CC0)); IntOGen LRP1B (driver in 70 cohorts (Act 39, LoF 27); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Potential cell surface proteins that bind and internalise ligands in the process of receptor-mediated endocytosis. Location: Membrane (UniProt). Locus 2q22.1-q22.2 (HGNC).
- Lung cancer: Open Targets association 0.67 with lung cancer (MONDO_0008903)
- Prostate cancer: Open Targets association 0.56 with prostate cancer (MONDO_0008315); IntOGen driver in 7 cohorts (PRAD)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 5 cohorts (PAAD, PANCREAS)
- Skin cancer: Open Targets association 0.64 with skin cancer (MONDO_0002898); IntOGen driver in 1 cohort (SKIN)
- Oesophageal cancer: Open Targets association 0.53 with oesophageal cancer (MONDO_0007576); IntOGen driver in 4 cohorts (ESCA)
- Breast cancer: Open Targets association 0.59 with breast cancer (MONDO_0007254); IntOGen driver in 4 cohorts (BRCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 39 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 27 cohorts; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"LRP1B" OR ABSTRACT:"LRP1B" OR TITLE:"LDL receptor related protein 1B" OR ABSTRACT:"LDL receptor related protein 1B" OR TITLE:"Low-density lipoprotein receptor-related protein 1B" OR ABSTRACT:"Low-density lipoprotein receptor-related protein 1B" OR TITLE:"LRP-DIT" OR ABSTRACT:"LRP-DIT" OR TITLE:"LRPDIT" OR ABSTRACT:"LRPDIT") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LRP1B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetETV5
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetSMAD3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetETV1
Shares Lung cancer (all types), Breast cancer (all types), CIViC, IntOGen.
- TargetNCOR1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetFUBP1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetBARD1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetGRIN2A
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetPIK3CB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.